There are currently 543 clinical trials in Madison, Wisconsin looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Wisconsin, University of Wisconsin Hospital and Clinics, University of Wisconsin-Madison and University of Wisconsin Carbone Cancer Center - University Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Recruiting
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: University of Wisconsin-Madison Hospital and Health Clinic, Madison, Wisconsin
Conditions: Carcinoma, Non-Small-Cell Lung, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms, Colorectal Neoplasms
Celecoxib for ENT Pain Management
Recruiting
The goal of this clinical trial is to find out whether pain can be managed after an operation with celecoxib instead of oxycodone. The main question it aims to answer is if use of celecoxib plus Tylenol reduces the need for oxycodone. Researchers will compare the combination of celecoxib and Tylenol to a placebo to find out whether celecoxib works to manage pain. Participants will: * Take celecoxib, or a placebo, plus Tylenol with opioids as needed * Keep a diary of their pain between visits... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Parotidectomy
Cervical Plexus Hydrodissection With D5W for PTSD
Recruiting
PTSD is a chronic mental health condition that drastically reduces an individual's quality of life Dextrose injection with a small needle has been used for chronic pain patients and observational results have shown it to be effective in reducing anxiety, brain fog, and depression in patients with PTSD. This randomized trial will compare dextrose injection with a delayed/usual treatment control.
Gender:
ALL
Ages:
Between 19 years and 90 years
Trial Updated:
03/01/2025
Locations: Eric Phillippi M.D. Clinic, Madison, Wisconsin
Conditions: PTSD
A Prospective Sub-Study of the Global Hypophosphatasia Registry
Recruiting
In this prospective observational sub-study, participants with pediatric-onset hypophosphatasia (HPP) (perinatal/infantile- or juvenile-onset) of any age will be followed for a minimum of 5 years at sites in the United States and potentially 1 or 2 other countries.
Gender:
ALL
Ages:
All
Trial Updated:
02/26/2025
Locations: Clinical Trial Site, Madison, Wisconsin
Conditions: Hypophosphatasia
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
Recruiting
This protocol will enroll patients with pancreatic adenocarcinoma and adenosquamous carcinoma (Cohort 1), gastrointestinal/pancreatic neuroendocrine neoplasms with Ki-67 \> 20% (Cohort 2) and neuroendocrine prostate carcinoma (Cohort 3)). Each cohort will have its own interim analysis after enrollment of 10 patients. Subjects will be given a one-month (28 day) supply of study drug (ESK981). Subjects will be instructed to take 4 capsules, with or without food, once per day for 5 consecutive cale... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Pancreatic Adenocarcinoma, Adenosquamous Carcinoma, Pancreatic Neuroendocrine Tumor, Pancreatic Neuroendocrine Carcinoma, Gastrointestinal Neuroendocrine Tumor, Gastrointestinal Neuroendocrine Carcinoma, Neuroendocrine Prostate Carcinoma
Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Recruiting
Patient will be treated with neratinib, an aromatase inhibitor and trastuzumab for 24 weeks prior to surgery, following an initial 3 weeks of neratinib alone, aromatase inhibitor alone or the combination of neratinib and an aromatase inhibitor. A breast biopsy will be performed prior to Day 1 of week 4 of treatment. Following surgery, patients will receive standard of care HER2-directed and endocrine therapy at the treating physician's discretion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Breast Cancer, HER2-positive Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 Mg) Intravitreal Implants Vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
Recruiting
This randomized controlled trial will evaluate the effect of intravitreal faricimab or fluocinolone acetonide (FAc) intravitreal implant compared with observation on long-term visual acuity following treatment of choroidal melanoma with iodine-125 plaque brachytherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: The Board of Regents of the University of Wisconsin System, Madison, Wisconsin
Conditions: Radiation Retinopathy, Visual Impairment
PEDI Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcus Study
Recruiting
The objective of the Pediatric Epidemiological Data and Incidence (PEDI) PANDAS study is to demonstrate the feasibility of enrollment and retention of subjects in a study to determine the incidence and natural history of children with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) with regard to spectrum, course and outcome. The investigators aim to demonstrate they can recruit and retain 85% of children who are eligible for this study. Eligible children are those who fit criteria for PA... Read More
Gender:
ALL
Ages:
Between 3 years and 17 years
Trial Updated:
02/17/2025
Locations: UW School of Medicine and Public Health, Madison, Wisconsin
Conditions: PANS, PANDAS
AB-1002 in Patients With Class III Heart Failure
Recruiting
This is a Phase 1, prospective, multi-center, open-label, sequential dose escalation study to explore the safety, feasibility, and efficacy of a single intracoronary infusion of AB-1002 in patients with NYHA Class III heart failure. Patients with non-ischemic cardiomyopathy will be enrolled until up to 17 subjects have received infusions of investigational product. All patients will be followed until 12 months post treatment intervention, and then undergo long-term follow-up via semi-structured... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: University of Wisconsin at Madison, Madison, Wisconsin
Conditions: Congestive Heart Failure, Heart Failure, Heart Disease, Ischemic, Cardiovascular Diseases, Heart Failure, Systolic, Heart Failure,Congestive, Heart Arrhythmia, Heart Failure, Diastolic, Heart; Complications
Prospective Registry to Evaluate Outcomes of NanoBone® Bone Graft in Acute Trauma
Recruiting
This multicenter prospective patient registry was developed with the aim of documenting how orthopedic surgeons are utilizing the NanoBone products in acute trauma cases along with relevant patient outcomes. These outcomes include radiographic measures such as fracture healing, instrumentation integrity, and clinical outcomes (symptom and function improvement) based on investigator and patient-based outcome assessments.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: SSM Health St. Mary's Hospital, Madison, Wisconsin
Conditions: Fractures, Bone
Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients
Recruiting
This study is being done to find out the best time to start medication for Hepatitis C Virus (HCV) in HCV-negative recipients of HCV-positive (HCV D+/R-) kidney transplants. Participants will be randomized into one of two groups: Arm 1 - Prophylaxis: This group will start the HCV medication before transplant and will take a shorter course of HCV medication for 2 weeks. Arm 2 - Transmit and Treat: This group will start the HCV medication after transplant and will take the full course (12 weeks)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/07/2025
Locations: University of Wisconsin, Madison, Madison, Wisconsin
Conditions: HCV
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
Recruiting
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their ba... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Atrial Fibrillation, Stroke, Bleeding